This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult Subjects

Inclusion Criteria:

- Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline
phosphatase and bilirubin <=1.5x upper limit of normal (ULN) (isolated bilirubin
>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).

- Healthy as determined by a responsible and experienced physician, based on a medical
evaluation including medical history, physical examination, laboratory tests and
cardiac monitoring. - A subject with a clinical abnormality or laboratory
parameters outside the reference range for the population being studied may be
included only if the Investigator and the GlaxSmithKline (GSK) Medical Monitor agree
that the finding is unlikely to introduce additional risk factors and will not
interfere with the study procedures.

- Male or female between 18 and 60 years of age inclusive, at the time of signing the
informed consent.

- A female subject is eligible to participate if she is of: Non-childbearing potential
defined as pre-menopausal females with a documented tubal ligation or hysterectomy;
or postmenopausal defined as 12 months of spontaneous amenorrhea. To confirm
post-menopausal status, a blood sample for simultaneous follicle stimulating hormone
(FSH) >40 MlU/ml and estradiol <40 pg/ml (<147 pmol/L) is confirmatory. Male
subjects with female partners of child-bearing potential must agree to use the
contraception methods. This criterion must be followed from the time of the first
dose of study medication until the final follow-up visit.

- Body weight >=50 kg and body mass index (BMI) within the range 19 to 31 kg/m2
(inclusive).

- Capable of giving written informed consent, which includes compliance with the
requirements and restrictions listed in the consent form.

Exclusion Criteria:

- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
result within 3 months of screening or positive Human Immunodeficiency Virus (HIV)
antibody.

- Current or chronic history of liver disease, or known hepatic or biliary
abnormalities.

- Any clinically significant central nervous system (e.g., seizures), cardiac,
pulmonary, metabolic, renal, hepatic or gastrointestinal conditions or history of
such conditions that, in the opinion of the investigator may place the subject at an
unacceptable risk as a participant in this trial or may interfere with the
absorption, distribution, metabolism or excretion of drugs.

- A screening or Day -2 urinalysis positive for protein or glucose (greater than
"trace" findings of protein or glucose).

- A serum creatinine value between screening and Day -2 visit that is increased by more
than 0.2 mg/dL (or 15.25 umol/L) changes.

- History of photosensitivity to quinolones and tendon rupture.

- Unwillingness to commit to avoid excessive exposure to sunlight which would cause a
sunburn reaction from first dose up to and including the follow-up visit.

- A positive urine test for drugs of abuse or alcohol (or alcohol breath test) at
screening or Day -2.

- History of drug abuse within 6 months of the study

- History of smoking or use of nicotine containing products within 3 months of
screening, or a positive urine cotinine indicative of smoking at screening.

- History of regular alcohol consumption within 6 months of the study defined as an
average weekly intake of >14 drinks for males or >7 drinks for females. One drink is
equivalent to 12 g of alcohol: 12 ounces (360 ml) of beer, 5 ounces (150 ml) of wine
or 1.5 ounces (45 ml) of 80 proof distilled spirits.

- The subject has participated in a clinical trial and has received a drug or a new
chemical entity within 30 days or 5 half-lives, or twice the duration of the
biological effect of any drug (whichever is longer) prior to the first dose of
current study medication.

- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
supplements within 7 days or 5 half-lives (whichever is longer) prior to the first
dose of study medication, or use of St. John's Wort within 14 days prior to the first
dose of study medication. By exception, the volunteer may take paracetamol or
acetaminophen (<=2 grams/day) up to 48 hours prior to the first dose of study
medication. However, the Investigator and GSK study team can review medication on a
case by case basis to determine if its use would compromise subject safety or
interfere with the study procedures or data interpretation.

- History of sensitivity to any of the study medications, or components thereof or a
history of drug or other allergy that, in the opinion of the investigator or GSK
Medical Monitor, contraindicates their participation.

- History of sensitivity to heparin or heparin-induced thrombocytopenia (if the
clinical research unit uses heparin to maintain intravenous cannula patency).

- Donation of blood in excess of 500 ml within 12 weeks prior to dosing.

- Consumption of red wine, seville oranges, grapefruit or grapefruit juice, pummelos,
exotic citrus fruits, grapefruit hybrids or fruit juices containing such products
from 7 days prior to the first dose of study medication.

- Screening ECG: Heart rate <40 and >100 bpm for males and <50 and >100 bpm for
females. PR Interval <120 and >220 msec, QRS duration <70 and >100 msec, QTcB or
QTcF interval >450msec. Evidence of previous myocardial infarction (does not include
ST segment changes associated with repolarization); any conduction abnormality
(including but not specific to left or right complete bundle branch block,
atrioventricular (AV) block [2nd degree or higher], Wolf Parkinson White [WPW]
syndrome), sinus pauses >3 seconds, non-sustained or sustained ventricular
tachycardia (>=3 consecutive ventricular ectopic beats) or any significant arrhythmia
which, in the opinion of the principal investigator and GSK medical monitor, will
interfere with the safety of the individual subject.

- Screening holter monitoring shows one or more of the following: any symptomatic
arrhythmia (except isolated extra systoles); sustained cardiac arrhythmias (such as
atrial fibrillation or flutter, supraventricular tachycardia (SVT) [>10 consecutive
beats]); sinus tachycardia (or SVT) >150 bpm; non-sustained or sustained ventricular
tachycardia (defined as >=3 consecutive ventricular ectopic beats); any conduction
abnormality (including but not specific to left or right complete bundle branch
block, AV block [2nd degree or higher in an awake subject], WPW syndrome, other
pre-excitation syndromes); symptomatic sinus pause or sinus pause >3 seconds - unless
patient is straining, vomiting, or having some other type of hypervagal response; 300
or more supraventricular ectopic beats in 24 hours; 250 or more ventricular ectopic
beats in 24 hours; Ischemia, diagnosed by a sequence of EKG changes that include flat
or down sloping ST-segment depression >0.1 mV, with a gradual onset and offset that
lasts for a minimum period of 1 minute. Each episode of ischemia must be separated
by a minimum duration of at least 1 minute, during which the ST segment returns back
to baseline (1x1x1 rule).

- Unwillingness or inability to follow the procedures outlined in the protocol.

- Subject is mentally or legally incapacitated.

- Neutrophil count <2000 cells per microliter (a single repeat is allowed for
eligibility determination).